WO2024218609 - COMPOSITION AND METHOD FOR INDUCING LUTEOLYSIS

National phase entry is expected:
Publication Number WO/2024/218609
Publication Date 24.10.2024
International Application No. PCT/IB2024/053454
International Filing Date 09.04.2024
Title **
[English] COMPOSITION AND METHOD FOR INDUCING LUTEOLYSIS
[French] COMPOSITION ET MÉTHODE D'INDUCTION DE LA LUTÉOLYSE
Applicants **
WELFARE CONCEPTS LIMITED 301r Botany Road, Golflands, Auckland, 2013, NZ
Inventors
TUCKER, Ian George 301r Botany Road, Golflands Auckland, 2013, NZ
BHUSAL, Prabhat 301r Botany Road, Golflands Auckland, 2013, NZ
WALKER, Greg 301r Botany Road, Golflands Auckland, 2013, NZ
MCDOUGALL, Scott 301r Botany Road, Golflands Auckland, 2013, NZ
EMSLIE, Forbes Richard 301r Botany Road, Golflands Auckland, 2013, NZ
Priority Data
2023901142   18.04.2023   AU
front page image
Application details
Total Number of Claims/PCT *
Number of Independent Claims *
Number of Priorities *
Number of Multi-Dependent Claims *
Number of Drawings *
Pages for Publication *
Number of Pages with Drawings *
Pages of Specification *
*
*
International Searching Authority
*
Applicant's Legal Status
*
*
*
*
*
Entry into National Phase under
*
Translation

Recalculate

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country StagesTotal
China Filing2064
EPO Filing, Examination16959
Japan Filing530
South Korea Filing575
USA Filing, Examination10035
MasterCard Visa

Total: 30163

The term for entry into the National Phase has expired. This quotation is for informational purposes only

Abstract[English] An injectable sustained release composition comprising a prostaglandin, formulated to release the prostaglandin in a sustained manner, and a method of inducing luteolysis of a functional corpus luteum in an animal by the sustained administration of a prostaglandin such as PGF2α, preferably cloprostenol.[French] L'invention concerne une composition injectable à libération prolongée comprenant une prostaglandine, formulée pour libérer la prostaglandine de manière prolongée, et une méthode d'induction de la lutéolyse d'un corps luteum fonctionnel chez un animal par l'administration prolongée d'une prostaglandine telle que PGF2α, de préférence la cloprosténol.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙